<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517085</url>
  </required_header>
  <id_info>
    <org_study_id>401GSDIA01</org_study_id>
    <secondary_id>1706-1617</secondary_id>
    <nct_id>NCT03517085</nct_id>
  </id_info>
  <brief_title>Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)</brief_title>
  <official_title>A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6- Phosphatase (G6Pase) in Adults With Glycogen Storage Disease Type Ia (GSDIa)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the safety of single doses of DTX401,
      including the incidence of dose-limiting toxicities (DLTs) at each dose level.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs), Treatment-emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Time (Minutes) to First Hypoglycemic Event During a Controlled Fasting Challenge at Weeks 6, 12, 24, and 52</measure>
    <time_frame>Baseline and Weeks 6, 12, 24, and 52</time_frame>
    <description>The change from baseline in time (in minutes) to first hypoglycemic event (defined as glucose &lt;60 mg/dL [&lt;3.33 mmol/L]) during a controlled fasting challenge after IV administration of DTX401).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>GSD1</condition>
  <arm_group>
    <arm_group_label>DTX401 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTX401 solution for intravenous (IV) infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTX401 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTX401 solution for intravenous (IV) infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTX401 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTX401 solution for intravenous (IV) infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DTX401</intervention_name>
    <description>DTX401 administered as a single peripheral IV infusion</description>
    <arm_group_label>DTX401 Dose 1</arm_group_label>
    <arm_group_label>DTX401 Dose 2</arm_group_label>
    <arm_group_label>DTX401 Dose 3</arm_group_label>
    <other_name>AAV8G6PC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males and females ≥18 years of age

          -  Documented GSDIa with confirmation by molecular testing

          -  Documented history of ≥1 hypoglycemic event with blood glucose &lt;60 mg/dL (&lt;3.33
             mmol/L)

          -  Patient's GSDIa disease is stable as evidenced by no hospitalization for severe
             hypoglycemia during the 4-week period preceding the screening visit

        Key Exclusion Criteria:

          -  Anti-AAV8 neutralizing antibody titer ≥1:5

          -  Screening or Baseline (Day 0) blood glucose level &lt;60 mg/dL (&lt;3.33 mmol/L)

          -  Liver transplant, including hepatocyte cell therapy/transplant

          -  Presence of liver adenoma &gt;5 cm in size

          -  Presence of liver adenoma &gt;3 cm and ≤5 cm in size that has a documented annual growth
             rate of ≥0.5 cm per year

          -  Significant hepatic inflammation or cirrhosis as evidenced by imaging or any of the
             following laboratory abnormalities: alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) &gt; upper limit of normal (ULN), total bilirubin &gt;1.5 × ULN,
             alkaline phosphatase &gt;2.5 × ULN

        Note additional inclusion/exclusion criteria may apply, per protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ultragenyx Pharmaceutical Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCONN Health</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-3213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Health - McGovern Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children Hospital, McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces Servicio Pediatria</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glycogen storage disorder Ia</keyword>
  <keyword>AAV</keyword>
  <keyword>gene therapy</keyword>
  <keyword>von Gierke disease</keyword>
  <keyword>glucose metabolism disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

